ºÚÁϳԹÏÍø

CLEVELAND - Investigators at ºÚÁϳԹÏÍø School of Medicine received a $6.75 million Program Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to study the role of innate immunity in inflammatory bowel disease (IBD). For years, scient...

CLEVELAND - A mutation on the surface of human red blood cells provides protection against malaria caused by the parasite Plasmodium vivax, research led by ºÚÁϳԹÏÍø School of Medicine shows. The minute change, at a single position of red blood cell surface protein called the ...

One of the earliest known impairments caused by Alzheimer’s disease—loss of sense of smell—can be restored by removing a plaque-forming protein in a mouse model of the disease, a study led by a ºÚÁϳԹÏÍø School of Medicine researcher finds. The study confirms that the protein,...

CLEVELAND - One of the earliest known impairments caused by Alzheimer’s disease - loss of sense of smell – can be restored by removing a plaque-forming protein in a mouse model of the disease, a study led by a ºÚÁϳԹÏÍø School of Medicine researcher finds. The study confirms t...

A hard probe inserted in the cerebral cortex of a rat model turns nearly as pliable as the surrounding gray matter in minutes, and it induces less of the tough scarring that walls off hard probes that do not change, researchers at ºÚÁϳԹÏÍø have found. In the first test of the...

CLEVELAND - ºÚÁϳԹÏÍø School of Medicine has received a $3.8 million grant from the National Heart, Lung, and Blood Institute (NHLBI) to study sleep apnea as a possible cause of atrial fibrillation (AF), the most commonly diagnosed type of arrhythmia, or irregular heart rhythm....

CLEVELAND - University Hospitals (UH) Case Medical Center, ºÚÁϳԹÏÍø School of Medicine and Lentigen Corporation announced today the initiation of a novel Phase I clinical trial of LG631 gene therapy for the protection of hematopoietic stem cells (HSCs) from the dose limiting t...

CLEVELAND - Today the Society for Integrative Oncology highlighted top research findings presented at the Eighth International Conference this week in Cleveland, Ohio, which is co-sponsored by ºÚÁϳԹÏÍø School of Medicine. More than 80 abstracts will be presented at the annual ...

CLEVELAND - ºÚÁϳԹÏÍø School of Medicine is honored to announce gifts to establish the inaugural Parker Hannifin – Helen Moss Cancer Research Foundation Professorship in Integrative Oncology. This professorship will establish the School of Medicine and its affiliate hospitals a...

CLEVELAND - Results of the pivotal Phase 3 clinical trial published in the Nov. 3, 2011 New England Journal of Medicine, find that the oral medication ivacaftor (VX-770) provides major, sustained improvement in lung function, growth and other signs and symptoms for cystic fibrosis (CF) patients. The...